Episode Details
Back to EpisodesLasofoxifene and ER+ Breast Cancer: Breakthroughs in Bone Metastasis Therapy
Description
In this episode, we explore the latest advances in treating estrogen receptor-positive (ER+) breast cancer, with a spotlight on lasofoxifene, a next-generation hormonal therapy showing promise for patients with advanced disease and bone metastasis.
You’ll learn:
- Why is such a common site for ER+ breast cancer metastasis
- How traditional endocrine therapies can weaken bone health and impact quality of life
- The unique dual action of lasofoxifene in both breast and bone tissue
- Key insights from the ELAINE-1, ELAINE-2, and ELAINE-3 clinical trials
- How lasofoxifene could reshape treatment for ESR1-mutated breast cancers
- Potential benefits beyond tumor control, including bone protection and fewer side effects
- The role of combination therapies with CDK4/6 and PI3K inhibitors in improving outcomes
- How future research in immune competence and precision oncology may refine treatment strategies
With its ability to suppress tumor growth while preserving bone density, lasofoxifene represents a promising shift in ER+ breast cancer therapy, one that prioritizes both survival and quality of life.
Blog Link: New Advances in ER+ Breast Cancer Therapy
Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education.
Author: Dr. CHRISTINA NG VAN TZE
📍 Visit us at oncolifecentre.com
📞 Call: +603-2242-2620
📧 Book a consultation or ask a question — we're here to support your journey.